Format

Send to

Choose Destination
Curr Diab Rep. 2017 Sep 27;17(11):112. doi: 10.1007/s11892-017-0942-8.

Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Author information

1
Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. achait@uw.edu.
2
Division of Endocrinology, New York University, New York, NY, USA.

Abstract

PURPOSE OF REVIEW:

This article reviews current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD). It reviews strategies to reduce diabetes-associated CVD, including reducing low-density lipoprotein levels, lowering triglycerides, and increasing high-density lipoproteins (HDL). Special considerations, such as the multifactorial chylomicronemia syndrome and partial lipodystrophy, and the role of glucose-lowering strategies in the management of diabetic dyslipidemia are discussed.

RECENT FINDINGS:

The strongest evidence to date for reducing CVD in diabetes comes from the use of statins. While triglyceride lowering remains inconclusive, an ongoing trial might provide some finality to this question. The role of increasing HDL remains elusive, and HDL cholesterol appears to be an unsatisfactory metric for monitoring therapy. The use of statins offers the best current way to reduce diabetes-associated CVD. However, several novel and promising approaches for the management of diabetic dyslipidemia aimed at reducing CVD are in the pipeline.

KEYWORDS:

Atherosclerosis; High-density lipoproteins; Low-density lipoproteins; Metabolic syndrome; Statins; Triglycerides

PMID:
28956258
DOI:
10.1007/s11892-017-0942-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center